Know Labs, Inc. 2024 10-K: Assets $108M, Liabilities $80M

TL;DR

Know Labs 10-K filed: $108M assets, $80M liabilities, $1.7M revenue, $10k net loss. FY24.

AI Summary

Know Labs, Inc. filed its 10-K for the fiscal year ending September 30, 2024. The company reported total assets of $108,097,936 and total liabilities of $80,358,463. During the fiscal year, Know Labs, Inc. generated $1,785,800 in revenue and incurred a net loss of $10,161. The company's principal executive offices are located at 619 Western Avenue, Suite 610, Seattle, WA 98104.

Why It Matters

This filing provides a comprehensive overview of Know Labs, Inc.'s financial health and operational performance for the fiscal year 2024, crucial for investors assessing the company's stability and future prospects.

Risk Assessment

Risk Level: medium — The company has significant liabilities relative to its revenue and a net loss, indicating potential financial strain.

Key Numbers

• $108.1B — Total Assets (As of September 30, 2024)
• $80.4B — Total Liabilities (As of September 30, 2024)
• $1.8M — Revenue (For the fiscal year ended September 30, 2024)
• $10K — Net Loss (For the fiscal year ended September 30, 2024)

Key Players & Entities

• KNOW LABS, INC. (company) — Filer
• 09-30-2024 (date) — Fiscal Year End
• $108,097,936 (dollar_amount) — Total Assets
• $80,358,463 (dollar_amount) — Total Liabilities
• $1,785,800 (dollar_amount) — Revenue
• $10,161 (dollar_amount) — Net Loss
• 619 Western Avenue, Suite 610, Seattle, WA 98104 (location) — Business Address

FAQ

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share KNW NYSE American LLC Se

Filing Documents

• knwn_10k.htm (10-K) — 1640KB
• knwn_ex42.htm (EX-4.2) — 27KB
• knwn_ex19.htm (EX-19) — 61KB
• knwn_ex211.htm (EX-21.1) — 1KB
• knwn_ex311.htm (EX-31.1) — 10KB
• knwn_ex312.htm (EX-31.2) — 11KB
• knwn_ex321.htm (EX-32.1) — 4KB
• knwn_ex322.htm (EX-32.2) — 4KB
• 0001654954-24-014480.txt ( ) — 6177KB
• knwn-20240930.xsd (EX-101.SCH) — 63KB
• knwn-20240930_lab.xml (EX-101.LAB) — 358KB
• knwn-20240930_cal.xml (EX-101.CAL) — 43KB
• knwn-20240930_pre.xml (EX-101.PRE) — 316KB
• knwn-20240930_def.xml (EX-101.DEF) — 217KB
• knwn_10k_htm.xml (XML) — 686KB

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations. 43 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk. 48 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data. 48 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure. 48 Item 9A.

Controls and Procedures

Controls and Procedures. 49 Item 9B. Other Information. 49 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections. 49 PART III Item 10. Directors, Executive Officers and Corporate Governance. 50 Item 11.

Executive Compensation

Executive Compensation. 56 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. 63 Item 13. Certain Relationships and Related Transactions, and Director Independence. 65 Item 14. Principal Accounting Fees and Services. 68 PART IV Item 15. Exhibit and Financial Statement Schedules. 69 Item 16. Form 10-K Summary. 2 Table of Contents INTRODUCTORY NOTES Use of Terms Except as otherwise indicated by the context and for the purposes of this report only, references in this report to "we," "us," "our" and "our company" are to Know Labs, Inc., a Nevada corporation, and its consolidated subsidiaries. Special Note Regarding Forward-Looking Statements This report contains forward-looking statements that are based on our management's beliefs and assumptions and on information currently available to us. All statements other than statements of historical facts are forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about: our goals and strategies; our future business development, financial condition and results of operations; expected changes in our revenue, costs or expenditures; growth of and competition trends in our industry; our expectations regarding demand for, and market acceptance of, our products; our expectations regarding our relationships with investors, institutional funding partners and other parties with whom we collaborate; fluctuations in general economic and business conditions in the markets in which we operate; and relevant government policies and regulations relatin

BUSINESS

ITEM 1. BUSINESS. Overview Know Labs, Inc. (the "Company") is an emerging leader in non-invasive medical diagnostics. We are focused on the development and commercialization of our proprietary sensor technology utilizing radio and microwave dielectric spectroscopy. Our sensor technology elicits a dielectric response that is unique for every molecule. It is based upon first principles of physics. We believe that our patented technology is capable of uniquely identifying and measuring almost any material or analyte using electromagnetic energy to detect, record, identify, and measure the unique "signature" of said materials or analytes and any rate of change when paired with our proprietary artificial intelligence and machine learning derived algorithms, While our core focus is on medical diagnostics, its technology is designed to be a true platform with a myriad of applications outside of the medical diagnostic realm. The first application of our sensor technology is in a product to non-invasively monitor blood glucose levels. Our device is intended to provide the user with real-time information on their blood glucose levels. During the quarter ended March 31, 2024 we announced our KnowU non-invasive wearable continuous glucose monitor working prototype device, which includes our proprietary sensor that has been used in internal clinical testing. We intend to expand our testing, both internally and externally, and to continue to refine the device over time, which will require Food & Drug Administration ("FDA") clearance before entering the market. Following FDA clearance of our non-invasive blood glucose monitoring device, Know Labs plans to expand its sensor technology to other non-invasive medical diagnostic applications. As a platform technology, we believe that it will be able to identify numerous other analytes in the human body that are important in medical diagnostics and human health and wellness. With data gathered over time by our sensor and analyzed

View Full Filing

View this 10-K filing on SEC EDGAR